Test-negative designs are commonplace in assessments of influenza vaccination effectiveness, estimating this value from the exposure odds ratio (OR) of vaccination among individuals treated for acute respiratory illness who test positive for influenza virus infection. This approach is widely believed to recover the vaccine direct effect by correcting for differential healthcare-seeking behavior among vaccinated and unvaccinated persons. However, the relation of the measured OR to true vaccine effectiveness is poorly understood. We derive the OR under circumstances of real-world test-negative studies. The OR recovers the vaccine direct effect when two conditions are met: (1) individuals' vaccination decisions are uncorrelated with exposure or susceptibility to the test-positive or test-negative conditions, and (2) vaccination confers "all-or-nothing" protection (whereby certain individuals have no protection while others are perfectly protected). Biased effect size estimates arise if either condition is unmet. Such bias may suggest misleading associations of vaccine effectiveness with time since vaccination or the force of infection of influenza. The test-negative design may also fail to correct for differential healthcare-seeking behavior among vaccinated and unvaccinated persons without stringent criteria for enrollment and testing. Our findings demonstrate a need to reassess how data from testnegative studies can inform policy decisions.
NOTATION
For consistency, we use notation from a previous study (10) where possible;; we list all parameters and definitions in Table  1 . Assume that ARI may result from influenza infection (I) or other causes (N). Susceptible individuals acquire infection at time-constant rates λ I and λ N ;; we show later that results hold for seasonal or otherwise time-varying acquisition rates λ(t). We define t=0 as the start of the influenza season, and assume individuals are vaccinated around this time (before extensive transmission).
Infections cause ARI with probability π I and π N , respectively. Out of the entire population P, a proportion of individuals (v) received vaccine. Because individuals who opted for vaccination may differ from others in their likelihood for seeking treatment for ARI, define the probability of seeking treatment for an ARI episode as µ V among the vaccinated and µ U among the unvaccinated;; we address how differential treatment seeking for test-positive and test-negative conditions influences estimates in a later section.
Because a single type or subtype of influenza typically dominates each season, assume that naturallyacquired immunity protects against within-season re-acquisition of influenza. The proportion of individuals remaining susceptible to infection at time t is thus -. / 0 . Assume further that the various non-influenza causes of ARI (N) are unlikely to provide immunity against one another, so that the full population remains at risk of N throughout;; we show later that this assumption does not impact estimates (Web
Appendix 1).
Consider two mechanisms by which vaccination protects against infection. Define ϕ as the proportion of individuals responding to vaccine, so that a proportion 1 − remain unaffected by vaccination;; here we assume individuals' likelihood of responding is unassociated with exposure or susceptibility to infection.
Among the responders, define θ as the hazard ratio for infection (measured relative to the hazard rate of infection among non-responders and unvaccinated persons) resulting from vaccine-derived protection (23, 24) . The special case where θ=0 and 0<ϕ<1 corresponds to a situation of "all-or-nothing" protection for responders and non-responders, respectively, while "leaky" protection for all recipients arises under ϕ=1 and 0<θ<1 (23, 24, 17) , whereby all vaccine recipients experience a reduced rate of acquiring infection. We note that this definition of "leaky" protection is unrelated to the relative risk for vaccine recipients and non-recipients to experience progression of infection to symptomatic disease (17) , and consider this issue in a subsequent section. The general circumstances of 0<ϕ<1 and 0<θ<1 correspond to an intermediate scenario of "leaky-or-nothing" protection. Perfect protection attains for θ=0 and ϕ=1, and no protection attains when ϕ=0 (no individuals respond to vaccination) or θ=1 (responders receive no protection). The vaccine direct effect on susceptibility to infection is the rate ratio of infection given vaccination:
This parameter is of interest in vaccine studies as the basis for calculating the effective reproductive number and the critical population to vaccinate (25) . To highlight design-level features most pertinent to the interpretation of test-negative studies, and in line with typical reporting of VE estimates, our analysis does not address heterogeneity in vaccine response beyond the consideration of "all-or-nothing" and "leaky-or-nothing" protection, nor do we address impacts of vaccination on infectiousness, as estimates from conventional test-negative studies do not capture indirect effects. We refer readers to previous studies addressing such issues in the contexts of differing study designs (17, (26) (27) (28) . Where applicable, we address sources of confounding in test-negative studies that may lead to incorrect inferences of heterogeneity in vaccine effects among individuals or over time.
PERFORMANCE OF THE ODDS RATIO UNDER VACCINATION UNCONFOUNDED BY EXPOSURE

OR SUSCEPTIBILITY TO THE CONDITIONS
Here we consider the case where individuals' decision-making about whether to receive influenza vaccine is uncorrelated with their a priori risk of acquiring influenza and test-negative conditions, and with the probability that these conditions would cause ARI (or another clinical endpoint of interest for study enrollment;; π I and π N ). To examine the potential for the test-negative design to correct for treatment-seeking biases, we allow vaccine recipients and non-recipients to have different probabilities of seeking treatment for ARI (µ V and µ U ), assuming for now that these probabilities are unaffected by the cause of the ARI. We relax this assumption in a later section. 
Under the assumption that test-negative infections are not immunizing, cumulative cases are proportional to the incidence rate and study duration:
We consider the case of immunizing test-negative outcomes in Web Appendix 1. Using the vaccineexposure OR measured from cumulative cases,
Under the special case of "all-or-nothing protection" (θ=0),
equal to the vaccine direct effect against infection. In contrast, under the special case of "leaky" protection for all recipients (ϕ=1),
resulting in a bias toward the null value of 0. This bias is nonexistent near t=0 (lim
but grows as t increases (lim
Despite the lack of data in test-negative studies on the population (or person-time) at risk for infection, this result (eq. 1a) is equal to VE measures from the relative risk in randomized controlled trials. While methods have previously been proposed to recover the vaccine effect on susceptibility through uses of population-at-risk or person-time-at-risk data (23, 29) , we note that the absence of such measurements presents a unique obstacle to bias correction in test-negative studies.
Studies may also measure time-specific ORs, for instance by stratifying analyses into sub-seasonal intervals (30) (31) (32) (33) or by interacting vaccination and time in logistic regression models fitted to individuallevel data (34, 35) . In comparison to ORs estimated from cumulative cases, such estimates are often sought to gauge differences over time in VE, for instance due to waning of protection. As the time increment approaches zero, terms included in the OR approach the ascertainment rates of test-positive and test-negative subjects. We therefore define this measurement as 
again reducing to
under "all-or-nothing" protection but allowing bias to persist under "leaky" protection for all recipients
Here bias is again nonexistent at t=0 and worsens as → ∞, further increasing with λ I . Intuitively, the bias arises due to differential depletion of vaccinated and unvaccinated susceptible individuals, consistent with other study designs (23, 36, 37) . Presuming the vaccine is efficacious, more unvaccinated than vaccinated individuals will have been depleted later in the epidemic, confounding instantaneous comparisons.
We illustrate functional forms of 1 − E ( ) and 1 − N ( ) under scenarios of "leaky" and "leaky-ornothing" protection in Figure  1 and rates in the range of 20-40% for seasonal influenza (38, 39) and up to 47% for influenza A(H1N1)pdm09 (40) among unvaccinated (and presumably susceptible) children, suggesting reported VE estimates may fall in the middle of this range in terms of bias;; differences in susceptibility across ages and risk strata may, however, result in differential rates of infection and differential degrees of bias in estimates (41) . The exposure-dependent biases we identify worsen with lower vaccine efficacy: for 1 − = 20%, estimated values fall 3.6%, 17.1%, and 32.4% below the true effect for λ I =0.001, 0.005, and 0.01, respectively.
Estimates based on the ascertainment rate (1 − Q ( )) would show greater bias at the same point in time: VE estimates are reduced by 4.6%, 25.2%, and 56.8% for a vaccine conferring 50% efficacy, and by 7.3%, 37.7%, and 78.9% for a vaccine conferring 20% efficacy.
Figure 2 illustrates how bias is further influenced by the contributions of vaccine response probabilities to
overall vaccine efficacy. For a vaccine conferring 50% efficacy based on 90% of individuals responding (so that = R-J.S R = 44.4%), and again defining λ I =0.001, 0.005, and 0.01 infections/person-day, 1 − E ( ) as of t=90 yields values subject to 2.0%, 10.0%, and 20.0% downward bias, respectively. With the same efficacy based on 60% of individuals responding (θ=16.7%), the degree of bias is reduced to 0.8%, 3.9%, and 8.2% below the true effect.
To aid interpretation in the context of previous studies (2, 11) , we also illustrate the modeled causal process using a directed acyclic graph ( Figure  3 ), revealing that the special case of "all-or-nothing" protection precludes bias from vaccine-derived protection against influenza infections occurring before the ARI episode for which an individual seeks care. We derive VE estimators accounting for additional real-world circumstances-including time-varying transmission intensity during an influenza season and the use of naturally immunizing test-negative endpoints-in Web Appendix 1, showing that the OR retains the biases identified under our simpler initial assumptions.
Conditions for sign bias
In some applications, testing for a protective or harmful effect of the vaccine may take priority over obtaining precise measurements of effect size. The conclusions of such hypothesis tests rest on an assumption that the OR is not subject to sign bias, reflecting the circumstance ( ) > 1 for an effective vaccine (as defined by the condition < 1), or ( ) < 1 for an ineffective vaccine (for which > 1). The plots of 1 − N ( ) in Figures  1  and  2 illustrate that VE estimates based on the ascertainment rate of cases may encounter sign bias. The OR measured from ascertainment rates reaches one-suggesting no vaccine effect-when the cumulative transmission to which a population has been exposed ( 8 × )
reaches a particular threshold:
we derive this threshold in Web Appendix 2. Once at least this proportion of the unvaccinated population has become immune to infection, cases will appear with higher frequency among vaccinated than unvaccinated individuals even when vaccine-derived protection does not wane. These circumstances demonstrate the need for caution in interpreting time-specific (continuous or sub-seasonal) VE measurements from test-negative studies (30) (31) (32) (33) , or for strategies to account for previous infection prevalence among vaccinated and unvaccinated persons.
PERFORMANCE OF THE ODDS RATIO UNDER DIFFERENTIAL EXPOSURE OR SUSCEPTIBILITY
OF VACCINATED AND UNVACCINATED PERSONS TO THE CONDITIONS
The test-negative design is typically employed in observational studies where individuals have received vaccination voluntarily. In contrast to assumptions in the above section that vaccination is uncorrelated with exposure or susceptibility to infection, variation in vaccine uptake across risk groups is wellrecognized (2) . For instance, preferential vaccine receipt has been reported among relatively healthy older adults (42, 43) and among persons prioritized for vaccination such as healthcare workers (who may have elevated risk of encountering infected persons) and individuals with underlying health conditions (who may be at risk for severe outcomes if infected) (44, 45) . This circumstance corresponds to the presence of a confounder ("G" in Figure  3 ) related to disease risk as well as vaccination.
Absent vaccine-derived protection, define 78 A8 and 7C AC as the relative rates at which individuals who seek vaccination would be expected to acquire influenza and test-negative conditions, respectively, measured against the expected rates among individuals who do not seek vaccination. These relative rates do not consider the biological effect of the vaccine, but only the counterfactual associated with vaccine-seeking status.
Accounting further for vaccine-induced protection, the ascertainment rates of test-positive and testnegative subjects are
resulting in cumulative case measures
Estimating VE from cumulative cases,
whereas the estimate based on ascertainment rates is
(2b)
These estimates reduce to
under "all-or-nothing" protection, and
Consider alternatively that 78 A8 and 7C AC are the relative risks of ARI given influenza and testnegative infections, respectively, for individuals who seek vaccination, measured against the risk among individuals who do not seek vaccination;; we again distinguish that these differences owe to factors other than vaccine-derived protection (17) , and consider vaccine protection against disease progression in a subsequent section. Incorporating π I and π N into the ORs formulated above,
Under "all-or-nothing" protection, 
These circumstances underscore that differential vaccine uptake among persons at high and low risk for infection or for symptoms given infection-a well-known phenomenon in observational studies of vaccines and other health interventions-may undermine causal interpretations of the OR in test-negative studies.
BIAS ASSOCIATED WITH DIFFERENTIAL TREATMENT SEEKING AMONG THE VACCINATED AND
UNVACCINATED
To this point we have considered ARI as a singular clinical entity and assumed all individuals seeking care for ARI are tested for influenza. However, different infections may cause clinically-distinct presentations influencing the likelihood that individuals seek treatment, or the likelihood that clinicians test for influenza (46) . Here we address the possibility for such a scenario to lead to selection bias from conditioning on the collider T (testing), the pathway V←H→T ←I in Figure  3 .
Consider that the spectrum of clinical presentations can be discretized into "moderate" (M) and "severe" 
when accommodating all possible factors that influence whether individuals are tested. Ensuring that the above condition is met can guide study implementation and circumvent possible biases owing to associations of vaccination with care-seeking given illness, receipt of clinical testing, and willingness to participate in the study.
Correction of bias through the use of clinical criteria for enrollment and testing A possible correction exists when enrollment and testing are tied to stringently-defined clinical criteria, i.e. criteria for which eq. 5 holds. For example, if tests are performed conditioning on cases resembling a welldefined and monotypic "Severe" entity (substituting ξ M =0 in eqs. 5a and 5b), the OR retains bias only from differential infection rates and symptom risk between the vaccinated and unvaccinated:
when measured from cumulative incidence, or 
Under the special case that a vaccine reduces risk of symptoms without protecting against infection for a vaccine protecting against symptoms only (θ=1).
IMPLICATIONS
Recent years have seen growing enthusiasm about the integration of data from observational studies in decisions surrounding influenza vaccine policy (50), in part based on belief that vaccine direct effectswhich have traditionally been measured in prospective, randomized controlled trials-can be recovered under the test-negative design (6, 10, 16, 24) . However, uptake of the test-negative design by researchers and policymakers has preceded thorough examination of its theoretical justification (14) . Our analysis highlights limitations to interpreting VE estimates based on the exposure OR from test-negative studies.
Our most troubling finding is that the OR measured by test-negative studies is unsuited to estimating the vaccine direct effect on susceptibility to infection even under circumstances consistent with randomized vaccine allocation, unless protection is known to follow an "all-or-nothing" mechanism of action. These results echo longstanding concerns about measurement of the effectiveness of "leaky" vaccines in casecontrol studies (23,51-53) as well as clinical trials (36, 37) , and occur because unvaccinated persons become immune via natural infection faster than unvaccinated ones. Researchers rarely know a priori to what extent a vaccine confers "leaky" or "all-or-nothing" protection, making it difficult to know under what circumstances studies may be subject to the resulting bias.
We also show that certain traditionally-recognized sources of confounding in observational studiesarising due to differential exposure or susceptibility to infection and symptoms among vaccinated and unvaccinated persons-persist under the test-negative design. Because resulting biases may lead to time-varying estimates of VE, declines in 1-OR over a season may not support inference of waning vaccine protection (31) (32) (33) (34) (35) . Last, whereas the test-negative design has been viewed as a strategy to eliminate treatment-seeking bias, we find that bias may persist under differential symptom severity for influenza and test-negative infections.
Several assessments of test-negative studies based on DAGs (2,11) have pointed to similar sources of confounding, and the practical importance of these findings has been debated amid uncertainty about the magnitude of associated bias in estimates (16) . The framework we have taken provides a basis for quantifying bias directly. We show that the OR of test-negative studies can supply VE estimates that are not equal to the causal vaccine effect on susceptibility and that sign bias may arise such that the instantaneous OR leads to incorrect inferences about whether a vaccine is effective or not. This is contrary to the frequent assumption that the OR provides, at minimum, a valid and direction-unbiased test of the null hypothesis of no causal effect (11) .
Other approaches have been taken to assess bias in test-negative studies. In informal comparisons, VE estimates from test-negative studies of live oral rotavirus vaccines and oral cholera vaccines have appeared similar to vaccine efficacy estimates from randomized controlled trials in the same settings (54, 55) . While these findings may suggest the biases we identify are not always large in practice, our study and others (36, 37) have pointed to potential sources of bias that may also affect estimates of the vaccine direct effect in randomized controlled trials. Moreover, seasonal influenza vaccine trials are not conducted on a year-to-year basis amid alterations to the strain composition of vaccines and changes to the immune profile of hosts. This has led to difficulty accounting for instances where conclusions of randomized controlled trials and test-negative studies have appeared to be in conflict. For instance, LAIV effectiveness has appeared poor in test-negative studies undertaken since the emergence in 2009 of a novel H1N1 influenza A virus (56, 57) , despite superior efficacy of LAIV over inactivated influenza vaccine among children in earlier randomized controlled trials (58) (59) (60) .
Many of the biases we identify result from differential acquisition of natural immunity among vaccinated and unvaccinated persons. The strength and duration of such immunity differs among infectious diseases for which test-negative studies have been undertaken to estimate VE;; specific implications for weaklyimmunizing infections such as rotavirus (18, 19) and respiratory bacterial agents (4, 22) should be assessed. Uses of the test-negative design in increasingly innovative applications, for instance an evaluation of cluster-randomized deployments of Wolbachia-infected mosquitoes to prevent dengue (61, 62) , further merit consideration in terms of transmission dynamic parameters such as we consider here.
STRATEGIES TO COUNTERACT BIAS
While our analysis identifies limitations to the validity of VE estimates based on the vaccine-exposure OR
under the test-negative design, the results highlight specific improvements that can be made to the interpretation of data from test-negative studies. We have shown that the use of strict clinical criteria or case definitions for enrollment and testing can reduce bias due to differential healthcare-seeking behavior among vaccinated and unvaccinated persons. Whereas test-negative studies typically stratify estimates according to influenza type/subtype or even the genetic clade, our findings suggest bias may persist if there are meaningful epidemiologic differences in risk factors for infection and disease among vaccinated and unvaccinated persons. This bias can be reduced by stratifying estimates to minimize within-stratum differences in exposure or susceptibility to infection among vaccinated and unvaccinated persons. While we point out the inability of test negative studies to measure "leaky" or "leaky-or-nothing" protection accurately, the persistence of such bias in randomized controlled trials echoes a broader need to consider epidemiological approaches for the measurement of imperfect forms of immunity (23, (51) (52) (53) .
Because biases resulting from the "leaky" nature of vaccine protection have lower impact in populations less exposed to transmission, VE estimates from early in the influenza season may be more reliable than those obtained later. This circumstance suggests a need to maximize statistical power for test-negative studies in the initial weeks or months of seasonal or pandemic influenza transmission. In addition, monitoring the cumulative incidence of infections in populations, for instance through serological studies, could facilitate correction for the differential prevalence of naturally-acquired immunity among vaccinated and unvaccinated persons. Evidence from test-negative studies of VE against influenza should be interpreted with the limitations we report here in mind, in particular for vaccination policymaking. Hazard ratio for infection resulting from vaccine-derived protection (among responders) α
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Relative risk of ARI given infection due to vaccine-derived protection ARI: acute respiratory illness FIGURES Figure  1 : Test-negative measures under "leaky" protection. We illustrate test-negative VE estimates obtained from the exposure odds ratio for a vaccine conferring "leaky" protection (ϕ=1) to all recipients;; This bias is not present in the case of all-or-nothing protection. Here, two distinct subgraphs can be envisioned. In the first, applicable only to the proportion (ϕ) of protected, vaccinated individuals, the path V→I pre →I t is not of concern, as Pr[I pre |V]=0. In the second, applying to the remaining proportion (1-ϕ) of unprotected individuals, the paths V→I pre →I t and V→I t are null, consistent with the situation where V=0.
Subsequent sections of this manuscript focus on other sources of bias evident in this DAG. The first concerns the impacts of a confounder (G) of exposure or susceptibility to influenza infection (here indicated in blue;; see also WEB APPENDIX 2 Here we derive the conditions under which the OR may inaccurately convey the protective (or riskincreasing) effect of vaccination, assuming no correlation of the decision to vaccinate with exposure or susceptibility to infection and disease. Consider the condition E ( ) = 1 − (1 − -. / 0 ) + 1 − -=. / 0 1 − -. / 0 > 1, which implies 1 − > 1 − 1 − -=. / 0 1 − -. / 0 . and thus > 1. Sign bias is present if < 1, so that the necessary conditions for sign bias cannot be met. In the converse situation, E ( ) < 1 implies < 1, which again cannot be true when > 1. Thus, sign bias does not occur in measurements based on cumulative cases, provided vaccination is uncorrelated with exposure or susceptibility to the infections. Because such confounding is likely in real-world studies, we assess resulting biases in a later section. 
WEB APPENDIX 3
Here we derive the OR under a scenario of differential severity of ARI caused by test-positive and testnegative conditions. Considering "moderate" and "severe" classes of symptomatic infection, ascertainment rates of subjects are 
